234 related articles for article (PubMed ID: 29727211)
1. Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Beech J; Germetaki T; Judge M; Paton N; Collins J; Garbutt A; Braun M; Fenwick J; Saunders MP
Future Oncol; 2018 Oct; 14(24):2531-2541. PubMed ID: 29727211
[TBL] [Abstract][Full Text] [Related]
2. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
3. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor inhibitor-induced hypomagnesemia: a survey of practice patterns among Canadian gastrointestinal medical oncologists.
Thangarasa T; Gotfrit J; Goodwin RA; Tang PA; Clemons M; Imbulgoda A; Vickers MM
Curr Oncol; 2019 Apr; 26(2):e162-e166. PubMed ID: 31043822
[TBL] [Abstract][Full Text] [Related]
5. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.
Bouché O; Ben Abdelghani M; Labourey JL; Triby S; Bensadoun RJ; Jouary T; Des Guetz G
World J Gastroenterol; 2019 Aug; 25(29):4007-4018. PubMed ID: 31413534
[TBL] [Abstract][Full Text] [Related]
6. Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer.
Annunziata MC; De Stefano A; Fabbrocini G; Leo S; Marchetti P; Romano MC; Romano I
Clin Drug Investig; 2019 Sep; 39(9):825-834. PubMed ID: 31264159
[TBL] [Abstract][Full Text] [Related]
7. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
8. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
[TBL] [Abstract][Full Text] [Related]
9. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.
Petrelli F; Ardito R; Ghidini A; Zaniboni A; Ghidini M; Barni S; Tomasello G
Oncology; 2018; 94(4):191-199. PubMed ID: 29393280
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
11. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Dote S; Itakura S; Kamei K; Hira D; Noda S; Kobayashi Y; Terada T
BMC Cancer; 2018 Oct; 18(1):957. PubMed ID: 30290786
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
[No Abstract] [Full Text] [Related]
13. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
15. Case of cetuximab-induced disseminated necrotic and maculopapular eruptions: Involvement of an epidermal growth factor receptor inhibitor with epidermal necrosis.
Namiki T; Omigawa C; Nojima K; Wakasa T; Tokoro S; Hanafusa T; Miura K; Yokozeki H
J Dermatol; 2018 Jan; 45(1):e3-e4. PubMed ID: 28971521
[No Abstract] [Full Text] [Related]
16. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
17. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
18. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
19. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
[No Abstract] [Full Text] [Related]
20. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
